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In cultured rat aortic smooth muscle cells, angiotensin II induced tyrosine phosphorylation of at least 9 proteins with molecular masses of 190, 
117, 105.82,79,77,73,45 and 40 kDa in time- and dose-dependent manners. Other vasoconstrictors uch as [Arglvasopressin, 5-hydroxytryptamine 
and norepinephrine induced the tyrosine phosphorylation of the same set of proteins as angiotensin II. The tyrosine phosphorylation of these pro- 
teins was mimicked by the protein kinase C-activating phorbol ester, phorbol 12 myristate 13-acetate, and the CaZ+ ionophorc, ionomycin. These 
results demonstrate that the vasoconstrictors timulate the tyrosine phosphorylation of several proteins in vascular smooth muscle cells and suggest 
that the tyrosine phosphorylation reactions are the events distal to the activation of protein kinase C and Ca2+ mobilization in the intracellular 
signalling pathways of the vasoconstrictors. 
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1. INTRODUCTION 
Stimulation of VSMC with vasoconstrictors such as 
ang II, AVP, 5HT and NE causes a rapid phospholipase 
C-mediated hydrolysis of inositol phospholipids 
resulting in the generation of two second messengers, 
diacylglycerol and inositol trisphosphate [l-4]. Diacyl- 
glycerol activates protein kinase C [5] whereas inositol 
trisphosphate mobilizes Ca’+ from intracellular Ca”’ 
stores [6] followed by the activation of Ca* + /cal- 
modulin-dependent protein kinases. Ca* + /calmodulin- 
dependent activation of myosin light chain kinase in- 
duces myosin light chain phosphorylation which in- 
itiates vascular smooth muscle contraction [7]. I-Iow- 
ever, little is known as to the molecular mechanisms by 
which these signalling pathways lead to the sustained 
contraction and growth of VSMC. 
possess a tyrosine kinase activity [8,9]. Recently, there 
is increasing evidence that protein-tyrosine phosphory- 
lation is+nvolved not only in proliferation and transfor- 
mation but also in other cellular responses uch as secre- 
tion from various cell types [lo-151. However, it has 
not yet been reported whether protein-tyrosine pkos- 
phorylation is related to the vasoconstrictor actions in 
VSMC. 
Protein-tyrosine phosphorylation has been con- 
sidered to be involved in proliferation and transforma- 
tion of cells because several viral transforming gene 
products and a number of growth factor receptors 
In the present study, we investigated the possible in- 
volvement of protein-tyrosine phosphorylation in the 
intracellular signalling pathways of vasosonstrictors in 
VSMC. The data reported here demonstrate that 
several vasoconstrictors including ang II, AVP, 5HT 
and NE induce the tyrosine phosphorylation of several 
proteins in cultured VSMC. These reactions are mimi- 
cked by the protein kinase C-activating phorbol esters 
and the Ca2+ ionophore, suggesting that these 
vasoconstrictors induce the protein-tyrosine phos- 
phorylation through the activation of protein kinase C 
and Cat+ mobilization. 
2. MATERIALS AND METHODS 
Abbreviarions: VSMC. vascular smooth muscle cells: ang 11, 
angiotensin II; AVP, [Arglvasopressin; 5HT, S-hydroxytryptamine; 
b!E, norepinephrine; PMA, phorbol 12-myristate 13-acetate: PDBu, 
phorbol 12,13-dibutyrate; 4o(-PDD. 4cu-phorbol 12,13-didecanoate; 
PDGF, platelet-derived growth factor; SDS-PAGE, sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis. 
2. I. Materials 
Correspondence address: Y. Kawahara, Department of Internal 
Medicine (1st Division), Kobe University School of Medicine, 7-S-l 
Kusunoki-cho, Chuo-ku, Kobe 650, Japan. 
VSMC were isolated from rat thoracic aorta by enzymatic dissocia- 
tion as described previously [16]. Mouse monoclonal anti-phospho- 
tyrosine antibody (IgM) was developed by immunizing with v-abl- 
expressing bacteria as described [17]. Growth media of hybridoma 
cells were purified by phosphotyrosine affinity column 
chromatography. Ang II, SHT, prazosin, (+)-propranolol, PMA, 
PDBu, 4ol-PDD and phosphoamino acids were purchased from 
Sigma (St. Louis, MO, USA). AVP, (*)-NE, ionomycin and recom- 
binant human PDGF-BB were from Wako Pure Chemical Industries 
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(Osaka, Japan), Aldrich (Milwaukee, WI, USA), Calbiochem (San 
Diego, CA, USA) and Collaborative Research (Bedford, MA, USA), 
respectively. Goat anti-mouse IgM conjugated with peroxidase was 
from Cappel (West Chester, PA, USA). Polyclonal rabbit anti-PDGF 
receptor fi subunit antibody was kindly supplied by Dr. T. Matsui 
(Kobe University, Kobe, Japan). Other materials and chemicals were 
obtained from commercial sources. 
2.2. Assay for protein-tyrosine phosphorylatton 
Confluent VSMC (passage levels9-18) were cultured in serum-free 
Dulbecco’s modified Eagle’s medium for 48 h and stimulated with 
various stimuli. The reactions were terminated by chilling the dishes 
on ice and washing twice with ice-cold phosphate-buffered saline. The 
cells were lysed in the buffer containing 50 mM Tris-HCI, pH 7.5, 1 
mM sodium vanadate, 1% Triton X-100, I mM phenylmethylsulfonyl 
Fluoride and 100 kallikrein-inactivating U/ml of aprotinin, and 
scraped From the dishes. Cell lysates were centrifuged for 15 min at 
I5 000 rpm using Beckman Microfuge E and the supernatants (I50 pg 
of protein) were subjected to SDS-PAGE (8-16% gradient gel) using 
the buffer system of Laemmli [IS]. The separated proteins were elec- 
trophoretically transferred to nitrocellulose membranes. 
Nitrocellulose blots were incubated with the mouse monoclonal anti- 
phosphotyrosine antibody and then with the peroxidase-labeled goat 
anti-mouse IgM. Peroxidase-labeled proteins were visualized by in- 
cubation with peroxidase color development reagents containing the 
enzyme substrate 3,3’-diaminobenzidine. 
3. RESULTS 
To detect phosphotyrosine-containing proteins, 
detergent extracts of VSMG were prepared in the 
presence of a phosphotyrosine phosphatase inhibitor, 
sodium vanadate, and subjected to SDS-PAGE follow- 
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Fig. I. Anti-phosphotyrosine immunoblot of VSMC stimulated with 
ang II and PDGF. Cultured rat aorzic VSMC were stimulated with 
100 nM and II For 2 min or with SO ng/ml PDGF For 5 min. Lane 1, 
control (Cant); lane 2, ang II; lane 3. PDGF. The positions of ang II- 
and PDGF-responsive proteins are indicated at right. The experiment 
shown respresents one of six independent trials which gave nearly 
Fig. 2. Effects of phosphoamino acids on anti-phosphotyrosine im- 
munoblot. Cultured rat aortic VSMC were stimulated with 100 nM 
ang II For 2 min or with 50 ng/ml PDGF For 5 min. lmmunoblot 
analysis was carried out in the absence or the presence of either 3 mM 
phosphotyrosine, phosphoserine or phosphothreonine during the in- 
cubation with the anti-phosphotyrosineantibody. Lanes 1,3,5 and 7. 
stimulated with ang II; lanes 2, 4, 6 and 8, stimulated with PDGF. 
Lanes I and 2, in the absence of phosphoamino acids (None); lanes 
3 and 4, phosphotyrosine (P-Tyr); lanes 5 and 6, phosphoserine (P- 
Ser); lanes 7 and 8, phosphothreonine (P-Thr). The experiment shown 
represents one of three independent rials which gave nearly identical 
identical results. results. 
ed by immunoblot analysis using the monoclonal anti- 
phosphotyrosine antibody. To test the reliability of this 
method, we first examined the effect of PDGF on 
tyrosine phosphorylation in VSMC since PDGP is well 
known to induce protein-tyrosine phosphorylation 
[ 19,201. Upon stimulation with PDGF, immunoreac- 
tivity of several proteins was increased which comprised 
the most heavily stained protein at about 200 kDa, at 
least 3 proteins above 200 kDa, and lower molecular 
mass proteins at about 190, 158, 117, 105, 82, 79, 77, 
73, 45 and 40 kDa (Fig. 1). These protein bands were 
specifically recognized on phosphotyrosine by the an- 
tibody because these protein bands were completely 
abolished when the blots were incubated with the an- 
tibody in the presence of 3 mM phosphotyrosine, but 
not in the presence of the same concentration of 
phosphoserine or phosphothreonine (Fig. 2). The 
200-kDa protein was recognized by anti-PDGF receptor 
p subunit antibody (data not shown). These results are 
consistent with the previous observations that PDGF 
induces tyrosine phosphorylation of several proteins in- 
cluding PDGF receptors in various cell types [19,20]. 
Under the same conditions, ang II also increased the im- 
12345678 
kl3a 
205 
110 
84 
47 
33 
Ang II PDGF Ang II PDGF Ang II PDGF Ang II PDGF 
None P-Tyr P-Ser P-Thr 
45 
Volume 285, number 1 FEBSLETTERS July 1991 
munoreactivity to the anti-phosphotyrosine antibody of 
at least 9 proteins at about 190, 117, 105, g&79,77,73, 
45 and 40 kDa (Fig. 1). All these protein bands migrated 
at the same positions on SDS-PAGE as those of PDGF- 
responsive 190-, 117-, 10% 8%, 79-, 77-, 73-, 45- and 
4O-kDa proteins. The appearance of these protein 
bands was also specifically blocked by the presence of 
phosphotyrosine (Fig. 2), indicating that these proteins 
were tyrosine-phosphorylated in response to ang II. The 
relative intensities of these protein bands were some- 
what varied from experiment to experiment but the 79-, 
77-, 73-, 45- and IO-kDa proteins were prominently 
phosphorylated by ang II in the repeated experiments. 
Fig. 3 shows the time course of ang II-induced 
protein-tyrosine phosphorylation. The tyrosine 
phosphorylation of the 73-kDa protein peaked around 
1 min after ang II stimulation followed by a gradual 
decline to nearly the basal level within 30 min. The 
tyrosine phosphorylation of the 45- and 40-kDa pro- 
teins peaked around 2 min and was declined to nearly 
the basal level within 15 min after ang II stimulation. 
Whereas the tyrosine phosphorylation of the 79- and 
77-kDa proteins peaked around 5 min and was sustain- 
ed above the basal level for at least 30 min after ang II 
stimulation. Fig. 4 shows the dose-response relation- 
ship of ang II-induced protein-tyrosine phosphoryla- 
tion. The maximal level of tyrosine phosphorylation of 
the 73-kDa protein was obtained at as low as 0. l-l nM, 
while the maximal levels of the 45- and 40-kDa proteins, 
and the 79- and 77-kDa proteins were obtained at l-10 
nM and IO-100 nM ang II, respectively. 
As shown in Fig. 5, AVP, %-IT and NE induced the 
tyrosine phosphorylation of the same set of proteins as 
ang II. The effect of NE was markedly inhibited by 
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Fig. 3. Time course of ang II-induced tyrosine phosphorylation. 
Cultured rat aortic VSMC were stimulated with 100 nM and ang II for 
various periods of time as indicated. The positions of the 79-, 77-, 73-, 
45- and 4O-kDa proteins arc indicated at right. The esperimcnt shown 
represents one of four independent rials which gave nearly identical 
results. trials which gave nearly identical results. 
Fig. 5. Effects of various vasoconstrictors on tyrosine phosphoryla- 
tion. Cultured rat aortic VSMC were stimulated for 2 min with 100 
nM ang II, IO0 nM AVP or 100 nM SHT. or with 10 r&l NE in the 
absence or presence of 10 pM prazosin or IO FM propranolol. Lane 
I. control (Cow); lane 2, ang II; lane 3, AVP; lane 4, SHT; lane 5, 
NE: lane 6, NE in the presence of prazosin (Pra); lane 7, NE in the 
presence of propranolol (Pro); lane 8, prazosin; lane 9, propranolol. 
Arrows indicate the positions of the 79-, 77-, 73-, 45-and 40.kDa pro- 
teins. The experiment shown represents one of three independent 
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Fig. 4. Dose-response relationship of ang II-induced tyrosine 
phosphorylation. Cultured rat aortic VSMC were stimulated for 2 
min with various concentrations of ang II as indicated. The positions 
of the 79-, 77-, 73-, 4% and 40-kDa proteins are indicated at right. The 
esperiment shown represents one of three independent rials which 
gave nearly identical results. 
equimolar concentration of the al-adrenergic receptor 
antagonist, prazosin, but not by the P-adrenergic recep- 
tor antagonist, propranolol, indicating that the effect 
of NE is mediated via cul-adrenergic receptors. 
All the vasoconstrictors described above induce the 
phospholipase C-mediated hydrolysis of inositol 
phospholipids resulting in the activation of two signal- 
COnt Ang II AVP 5HT NE NE NE Pra Pro 
+ e 
Pra Pro 
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Fig. 6. Effects of PMA and ionomycin on tyrosine phosphorylation. 
Cultured rat aortic VSMC were stimulated with 100 nM ang 11 for 2 
min, 100 nM PMA for 5 min or 2 gM ionomycin for 1 min. Lane 1, 
control (Cant); lane 2, ang II; lane 3, PMA; lane 4, ionomycin (lono). 
Arrows indicate the positions of the 79-, 77-, 73-, 4% and 40-kDa pro- 
teins. The experiment shown represents one of three independent 
trials which gave nearly identical results. 
ling pathways, diacylglycerol-protein kinase C and in- 
ositol trisphosphate-Ca2+ [l-4]. In the last set of ex- 
periments, we examined the relationships between these 
signalling pathways and the protein-tyrosine 
phosphorylation. Protein kinase C-activating phorbol 
ester, PMA, induced the tyrosine phosphorylation of 
the same set of proteins as the vasoconstrictors (Fig. 6). 
Another active phorbol ester, PDBu, also induced these 
reactions whereas 4a-PDD which does not activate pro- 
tein kinase C failed to induce the reactions (data not 
shown). Fig. 6 also shows that the vasoconstrictor- 
induced protein-tyrosine phosphorylation was mimick- 
ed by the Ca2 + ionophore, ionomycin. 
4. DISCUSSION 
We showed in the present study that ang II and other 
vasoconstrictors such as AVP, 5HT and NE stimulated 
protein-tyrosine phosphorylation of the same set of 
proteins in VSMC. These observations could reflect 
either the activation of tyrosine kinases or the inhibition 
of phosphotyrosine phosphatases during the action of 
these vasoconstrictors. The differences in the time 
courses and dose-response relationships of ang II- 
induced tyrosine phosphorylation of the individual pro- 
teins suggest that severai distinct tyrosine kinases 
and/or phosphotyrosine phosphatases are involved in 
these reactions. Although molecular mechanisms by 
which the vasoconstrictors activate tyrosine kinases or 
inhibit phosphotyrosine phosphatases are uncertain, 
the results of the present study provide the first 
demonstration of vasoconstrictor-induced protein- 
tyrosine phosphorylation in VSMC. 
We also demonstrated that the protein kinase C- 
activating phorbol esters and the Ca2+ ionophore 
stimulated the tyrosine phosphoryiation of the same set 
of proteins as the vasoconstrictors. Since all the 
vasoconstrictors described here activate two signalling 
pathways, diacylglycerol-protein kinase C and inositol 
trisphosphate-Ca2+ in VSMC [l-4], these observations 
strongly suggest that the vasoconstrictors induce the 
protein-tyrosine phosphorylation through the activa- 
tion of protein kinase C and Ca2 + mobilization. Con- 
sistent with this idea, current studies have shown that 
various protein kinase C-activating and Cat ’ -mobil- 
izing stimuli induce protein-tyrosine phosphorylation in 
their respective target cells such as thrombin and col- 
lagen in platelets [IO-121, carbachol in chromaffin cells 
[13] and crosslinking of membrane immunoglobulins in 
basophilic leukemia cells and B lymphocytes 115,211. 
Recently, Huckle et al. [22] have reported that ang II 
stimulates protein-tyrosine phosphorylation in Wl3 rat 
liver epithelial cells in a Cat *-dependent but protein 
kinase C-independent manner. The reason for the dif- 
ference between our results and theirs is not clear at pre- 
sent, but it may be due to the difference in cell types. 
The receptor-mediated tyrosine phosphorylation is 
essential for the mitogenic action of PDGF [23], but 
physiological roles of the vasoconstrictor-induced 
tyrosine phosphorylation in VSMC are at present en- 
tirely speculative. The results of the present study in- 
dicate that there are tyrosine-phosphorylated proteins 
common to both the vasoconstrictors and PDGF, and 
those specific for PDGF which include PDGF recep- 
tors. Since and II per se is not mitogenic for VSMC 
[24,X], these observations suggest that the tyrosine 
phosphorylation of the common substrates is not suffi- 
cient and the tyrosine phosphorylation of the PDGF- 
specific substrates is required for the mitogenic action 
for VSMC. Alternatively, the tyrosine phosphorylation 
of the common substrates may be responsible for the 
cellular responses common to the vasoconstrictors and 
PDGF such as contraction and protein synthesis 
[24-261. Identification of the individual substrate pro- 
teins is absolutely necessary to elucidate the precise 
roles of the vasoconstrictor-induced tyrosine phos- 
phorylation in VSMC functions. 
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